Printer Friendly

Deerfield provides USD 125m to Tris Pharm as growth capital.

BANKING AND CREDIT NEWS-October 12, 2018-Deerfield provides USD 125m to Tris Pharm as growth capital

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Deerfield has announced it provided USD 125 million as debt financing and to provide growth capital to Tris Pharma, Inc., the company said.

This financing allows Tris to expand its branded pharmaceutical portfolio with a particular focus on Attention Deficit Hyperactivity Disorder (ADHD), launch and promote new products and continue development of its drug development platform.

In addition to the financing, Deerfield and Tris plan to enter into a product development agreement to leverage Tris' proprietary drug delivery technology.

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Banking & Credit News (BCN)
Date:Oct 12, 2018
Words:128
Previous Article:Cetera Financial launches advisor alignment program.
Next Article:Glassbox closes USD 25m in funding to strengthen position as digital customer management platform.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |